Market Place
Sourcing Support
Vertex adds CDMO Lonza to Casgevy production network
24 Sep 2024 //
FIERCE PHARMA
Vertex-CRISPR And Bluebird Begin Sickle Cell Gene Therapies
18 Sep 2024 //
BIOSPACE
Vertex goes all in on September`s bumper awareness month push
04 Sep 2024 //
FIERCE PHARMA
Vertex to Participate in Upcoming September Investor Conferences
22 Aug 2024 //
BUSINESSWIRE
Vertex Reports Second Quarter 2024 Financial Results
01 Aug 2024 //
BUSINESSWIRE
Vertex: TRIKAFTA® Benefit Data At Cystic Fibrosis Conference
07 Jun 2024 //
BUSINESSWIRE
Vertex touts Casgevy sickle cell launch as bluebird makes progress Lyfgenia
06 May 2024 //
ENDPTS
Vertex Advances Inaxaplin into Ph 3 for the Treatment of APOL1-Mediated KD
01 Apr 2024 //
BUSINESSWIRE
Lonza, Vertex Break Ground for Cell Therapy Mfg. Facility
31 Aug 2023 //
CONTRACT PHARMA
Vertex Presents Positive VX-880 Results From Ongoing Phase 1/2 Study in Type 1 D
23 Jun 2023 //
BUSINESSWIRE
Two Aurinia execs are out — and CRISPR’s operations chief isn`t far behind
28 Oct 2022 //
ENDPTS
Vertex (VRTX) CF Drug Gets FDA Expanded Label for Toddlers Nasdaq
05 Sep 2022 //
NASDAQ
FDA lifts hold on Vertex`s diabetes stem cell therapy
06 Jul 2022 //
ENDPTS
Teva chief raids Vertex for his new global head of research and development
01 Jul 2022 //
ENDPTS
CRISPR Tx and Vertex take the air with interim CRISPR blood cell therapy data
11 Jun 2022 //
ENDPTS
Vertex to Present Data Demonstrating Significant Benefits of CFTR Modulators
10 Jun 2022 //
BUSINESSWIRE
Vertex`s Inaxaplin (VX-147) Granted BTD by U.S. FDA and PRIME Designation by EMA
08 Jun 2022 //
BUSINESSWIRE
Vertex to Participate in Goldman Sachs Healthcare Conference on June 15
08 Jun 2022 //
BUSINESSWIRE
Vertex Presents New Data from VX-880 PI/II Trial at ADA
06 Jun 2022 //
BUSINESSWIRE
Vertex and CRISPR Tx Announce Acceptance of Late-Breaking Abstract for CTX001
02 Jun 2022 //
BUSINESSWIRE
Vertex to Present New Data on VX-880 Clinical Trial at 82nd ADA
31 May 2022 //
BUSINESSWIRE
Group of Catalyst shareholders claims biotech could’ve sold assets 3 years ago
27 May 2022 //
ENDPTS
Vertex plots 500-person cell, genetic therapy R&D center
17 May 2022 //
FIERCEBIOTECH
Vertex Announces Further Expansion in the Boston Seaport
17 May 2022 //
BUSINESSWIRE
Vertex Falls After FDA Halts Diabetes Study in Surprise Move
03 May 2022 //
BLOOMBERG LAW
AbbVie cuts Galapagos cystic fibrosis med years after $45M buy
30 Apr 2022 //
FIERCEBIOTECH
Acadia`s prized pain drug from $52M buyout flops its first test
20 Apr 2022 //
ENDPTS
OrbiMed-backed biotech looks to challenge Vertex in cystic fibrosis
19 Apr 2022 //
ENDPTS
Vertex’s non-opioid painkiller meets goals in mid-stage studies
01 Apr 2022 //
STATNEWS
Vertex Announces Reimbursement Agreement in Australia for TRIKAFTA
26 Mar 2022 //
BUSINESSWIRE
Vertex Advances VX-147 Into Pivotal Clinical Development
22 Mar 2022 //
BUSINESSWIRE
Vertex to Present at Cowen’s 42nd Annual Health Care Conference on March 8
01 Mar 2022 //
BUSINESSWIRE
Vertex`s Trikafta posted megablockbuster sales in 2022
27 Jan 2022 //
FIERCEPHARMA
CRISPR, ViaCyte beat Vertex to the clinic with diabetes cell therapy
17 Nov 2021 //
ENDPTS
Boehringer takes next step in development of cystic fibrosis gene therapy
19 Oct 2021 //
BIOPHARMADIVE
Vertex Appoints Stuart A. Arbuckle as Chief Operating Officer
04 Aug 2021 //
BUSINESSWIRE
Vertex Start Phase 3 Development Program for New Once-Daily Triple Combo Regimen
29 Jul 2021 //
BUSINESSWIRE
Vertex Reports Second-Quarter 2021 Financial Results
29 Jul 2021 //
BUSINESSWIRE
Vertex Initiates Phase 2 Clinical Trial Program for VX-548
19 Jul 2021 //
BUSINESSWIRE
Vertex to Announce Second-Quarter 2021 Financial Results on July 29
16 Jul 2021 //
BUSINESS WIRE
Vertex Announces National Reimbursement Agreement in France for KAFTRIO
28 Jun 2021 //
BUSINESSWIRE
Vertex Reports New Portfolio Reimbursement Agreement in Italy Including KAFTRIO
26 Jun 2021 //
BUSINESSWIRE
Vertex Halted Development of Liver-Disease Drug
11 Jun 2021 //
FIERCE BIOTECH
Vertex discontinues VX-864 in alpha-1 antitrypsin deficiency
10 Jun 2021 //
BUSINESSWIRE
Vertex Announces U.S. FDA Approval for TRIKAFTA
09 Jun 2021 //
BUSINESSWIRE
CF Foundation backs a new round for a biotech upstart out Vertex
13 May 2021 //
ENDPTS
Vertex to Present at the Bank of America Securities 2021 Virtual Health
10 May 2021 //
BUSINESSWIRE
Vertex Announces New Drug Submission for Investigational Triple Combination
28 Dec 2020 //
BUSINESSWIRE
Vertex Announces New Drug Submission for Investigational Triple Combination
28 Dec 2020 //
BUSINESSWIRE
Vertex`s success kills off Savara`s experimental CF drug hopes
04 Sep 2020 //
FIERCEBIOTECH
Vertex and NHS Wales agree on Kaftrio reimbursement
24 Jul 2020 //
PHARMA TIMES
David Hallal bags another whopper round looking recruit more cell & gene therapy
31 Mar 2020 //
ENDPTS
Vertex`s cystic fibrosis portfolio to be made available across Northern
13 Nov 2019 //
PHARMAFILE
GSK opens $95M continuous production operation in Singapore
08 Jul 2019 //
FIERCE PHARMA
Pfizer’s DMD gene therapy safety data hand advantage to Sarepta
01 Jul 2019 //
FIERCE BIOTECH
The top 10 blockbuster drugs in the late-stage pipeline
19 Jun 2019 //
ENDPTS
Is CEO pay linked to drug prices? Investors failed to find out
30 May 2019 //
FIERCE PHARMA
Vertex’s Orkambi CF drug okayed for funding in Australia
20 Aug 2018 //
PHARMAPHORUM
After Hep C Flop, Has Vertex (VRTX) Learned From Its Past Mistakes?
18 Oct 2016 //
BIOSPACE
NICE denies cystic fibrosis patients access to Orkambi
01 Aug 2016 //
PHARMATIMES
